Although third-generation EGFR-TKIs have therapeutic advantages for NSCLC patients with the T790M mutation, most patients will become resistant to these agents and will eventually lead to disease progression (Zhang et al., 2020b). Here, EGFR is linked to non-small cell lung carcinoma.